Figure 5From: Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case studyStructure of MK2(47–366, T222E) bound to a lead compound. The micromolar-potency inhibitor was soaked into a Form IV crystal. The inhibitor, represented as a tan molecular surface, binds deeply in the ATP pocket of MK2(47–366, T222E) (rainbow coloring). Apo-MK2 (PDB entry 1KWP; light-grey) is shown for comparison.Back to article page